Tag: infliximab biosimilar

Switching from an originator biologic to a biosimilar is safe for most patients with stable chronic conditions. Evidence shows no meaningful difference in efficacy or safety, though psychological factors can affect perception. Cost savings are significant, and structured patient communication improves outcomes.

Recent-posts

How Governments Must Act on Reemerging Influenza Outbreaks

Oct, 13 2025

How to Report Side Effects after Switching to a Generic Medication

Jan, 15 2026

Heart Disease Risk Factors: Age, Family History, Smoking, and What You Can Do

Nov, 28 2025

Avanafil for Erectile Dysfunction in Men with Multiple Sclerosis: What You Need to Know

Nov, 6 2025

Buy Cheap Generic Topamax Online - Affordable Migraine & Seizure Relief

Oct, 11 2025